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Anemia is a common complication of chronic kidney disease (CKD). However, risk factors of anemia in CKD patients
in Singapore are not well established. Hence, a retrospective, case–control study involving non-dialysis CKD patients
was conducted to determine possible predictors of anemia in the local CKD population.
Non-dialysis adult CKD patients, not receiving renal replacement therapy or erythropoiesis-stimulating-agents were
included. Parameters collected included demographics e.g. age, sex and race; clinical data e.g. CKD stage and
medical/medication histories; and laboratory data e.g. serum electrolytes, urinary and hematologic parameters.
Patients were classified as anemic or non-anemic using a threshold hemoglobin level of 10 g/dL. The parameters
were evaluated for their predictive value for anemia development using multivariate logistical regression and
calculation of odds ratios. Statistical analyses were performed using STATA.
A total of 457 patients (162 anemic and 295 non-anemic) were analysed. Multivariate analysis showed that
probability of developing anemia was greater for patients with stage 5 CKD (OR 16.76, p < 0.001), with
hematological disorders (OR 18.61, p < 0.001) and with respiratory disorders (OR 4.54, p = 0.004). The probability of
developing anemia was lower for patients with higher previous hemoglobin concentration (OR 0.32, p < 0.001) and
in those receiving iron supplements (OR 0.44, p = 0.031). Gender and race were not found to be significant
predictors of anemia.
Risk of anemia is increased in patients with advanced CKD, haematological disorders, respiratory disorders, and
those not taking iron supplements. This study has increased our understanding of the patient subgroups at risk for
anemia.
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Chronic kidney disease (CKD) develops as a result of
progressive loss of renal function due to structural or
functional abnormalities of the kidney, and has import-
ant implications for health (KDIGO Work Group 2013).
In 2013, CKD was identified as the 8th leading cause of
death in Singapore (Ministry of Health, Singapore 2013).
The incidence of CKD has been on the rise locally in
Singapore as well as globally, causing it to become an in-
creasing health concern (National Registry of Diseases
Office, Singapore 2013; Ruggenenti et al. 2001). In 2010,
there were 267 new cases of end-stage renal disease
(ESRD) per million resident population (crude rate) in* Correspondence: phayapc@nus.edu.sg; priscillahow@nus.edu.sg
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provided the original work is properly creditedSingapore, up from 194 per million resident population
in 1999 (National Registry of Diseases Office, Singapore
2013). The mortality and economic burden of the disease
can be substantial (Valderrabano et al. 2001).
Anemia is a common complication that contributes to
the burden of CKD (Basile 2007). It is diagnosed in
adults and children >15 years old with CKD when the
hemoglobin (Hb) concentration is <13.0 g/dL in male
patients and <12.0 g/dL in female patients (KDIGO
Anemia Work Group 2012). While the primary cause of
anemia is the inadequate production of erythropoietin
by the kidneys to support erythropoiesis (Ramanath
et al. 2012), other factors may contribute to CKD-
associated anemia, including decreased red blood cell life
span, iron, folate and vitamin B12 deficiencies, blood loss,
and accumulation of toxic inhibitors of erythropoiesis
(McFarlane et al. 2008; Hsu et al. 2002).distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
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variable in its time of presentation and severity among
different individuals. Untreated anemia can also accelerate
the decline in renal function by causing renal hemodynamic
alterations and tissue hypoxia (Portolés et al. 2013; Iseki
and Kohagura 2007). Patients with CKD and anemia often
experience symptoms such as weakness, shortness of
breath, and are at increased risk of cardiovascular diseases
(CVD) and complications such as left ventricular hyper-
trophy (National Kidney Foundation 2006). This leads to
higher consumption of health-care resources and increased
risk of mortality (London et al. 2002).
Although full correction of anemia from low Hb con-
centrations have been shown to increase morbidity andPatients with a confirmed diagnosis of CKD who were 
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Fig. 1 Patient recruitment chartmortality in CKD patients (Singh et al. 2006; Drüeke
et al. 2006; Pfeffer et al. 2009), partial correction has
been shown to improve cardiac function (Hayashi et al.
2000), cognitive function (Pickett et al. 1999) and quality
of life in CKD patients (Revicki et al. 1995; Drüeke et al.
2006). It is thus necessary to identify predictors for
anemia in CKD patients so that prevention and manage-
ment strategies can be adopted early before complica-
tions develop. The third National Health and Nutrition
Examination Survey (NHANES) study conducted in
1988–1994 showed a significant increase in the preva-
lence of anemia as patients’ glomerular filtration rate
(GFR) fell below 60 mL/min (Hsu et al. 2002; Astor et al.
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Table 1 Patients’ demographic, clinical and laboratory parameters
Parameters Anemic patients Non-anemic patients
N Number (%) or mean ± SD N Number (%) or mean ± SD
Demographics
Age, years 162 68.8 ± 13.2 295 66 ± 13.8
Gender
(Female/Male) 162 91 (56.2) / 71 (43.8) 295 124 (42.0) / 171 (58.0)
Race
Chinese/Malay/Indian/Others 162 99 (61.1) / 34 (21.0) / 16 (9.9) / 13 (8.0) 295 202 (68.5) / 56 (19.0) / 18 (6.1) / 19 (6.4)
Clinical data
Weight, kg 67 61.8 ± 13.1 137 68.1 ± 15
Height, m 65 1.6 ± 0.1 135 1.6 ± 0.1
Body mass index, kg/m2 65 25.4 ± 4.8 133 27 ± 5.3
CKD stage
Stage 1/2/3/4/5 162 3 (1.9) / 8 (4.9) / 29 (17.9) / 52 (32.1) / 70 (43.2) 295 45 (15.3) / 0 (0.0) / 127 (43.1) / 104 (35.3) / 19 (6.4)
Laboratory data (serum levels), units
Current Hb, g/dL 162 9.2 ± 0.7 295 12.6 ± 1.7
Previous Hb, g/dL 162 9.9 ± 1.3 295 12.6 ± 1.7
Sodium, mmol/L 161 137.7 ± 3.8 292 138.1 ± 3.1
Potassium, mmol/L 161 4.5 ± 2.6 292 4.3 ± 0.5
Chloride, mmol/L 136 107 ± 5.8 257 106.1 ± 4
Bicarbonate, mmol/L 150 22.9 ± 3.9 270 24.7 ± 3.1
Urea, mmol/L 161 15.1 ± 8 292 10.5 ± 5.5
Creatinine, μmol/L 161 257 ± 188.7 293 174.3 ± 87.9
Calcium, mmol/L 150 2.2 ± 0.2 269 2.2 ± 0.1
Corrected calcium, mmol/L 99 2.3 ± 0.1 206 2.3 ± 0.1
Phosphate, mmol/L 148 1.3 ± 0.3 262 1.2 ± 0.2
Alkaline phosphatase, U/L 149 86.1 ± 58.5 262 73.4 ± 42.6
Albumin, g/L 145 34 ± 5.5 239 37.7 ± 4.2
Total cholesterol, mmol/L 128 4.6 ± 1.5 258 4.7 ± 1.3
Triglycerides, mmol/L 128 1.6 ± 0.8 258 1.8 ± 1.7
High-density lipoprotein, mmol/L 128 1.2 ± 0.4 257 1.2 ± 0.4
Low-density lipoprotein, mmol/L 128 2.7 ± 1.3 254 2.7 ± 1.1
White blood cells, x109/L 162 8.1 ± 4 295 7.8 ± 2.9
HbA1c, % 127 7 ± 1.5 193 7.4 ± 1.6
Iron, μmol/L 94 10.3 ± 5.7 80 11.4 ± 5.6
Ferritin, μg/L 97 397.9 ± 490.8 85 275.5 ± 520.0
Transferrin, mg/dL 94 186 ± 50.5 80 205.1 ± 53.6
Total iron binding capacity, μmol/L 94 48.4 ± 13.1 79 54.1 ± 12.7
Transferrin saturation, % 93 22.6 ± 11.9 79 22.2 ± 12.0
Intact parathyroid hormone, pmol/L 81 16.3 ± 15.4 129 11.9 ± 13.7
25-hydroxyvitamin D, μg/L 34 17.1 ± 11 60 22.4 ± 11.8
Folate, nmol/L 39 52.7 ± 71.2 44 27.8 ± 33.4
Vitamin B12, pmol/L 42 488.7 ± 260.4 50 450.6 ± 292.9
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2007; McClellan et al. 2004; Gilbertson et al. 2009;
Al-Khoury et al. 2006).
However, most of these studies were conducted using
the anemic CKD population from the US. The findings
of these studies might not be representative of our local
patient population due to differences in geographical lo-
cation, lifestyle, racial and genetic make-up. Additionally,
studies have shown that Hb concentrations vary between
races, with African-American individuals consistently
showing Hb concentrations 0.5 to 0.9 g/dl lower than
Whites or Asians (Denny et al. 2006; Cresanta et al.
1987; Pan and Habicht 1991).
Study aim
Risk factors of anemia in multi-ethnic CKD patients in
Singapore are not yet well established and no studies
have been done to assess potential local factors. As such,
a case–control study involving non-dialysis CKD pa-
tients with and without anemia was conducted to deter-
mine clinical and/or demographics parameters that can

























Clinical and demographic parameters
The patient recruitment process is illustrated in Fig. 1. A
total of 2806 patients had clinic visits during the study
period of January 2012 to September 2012. After screen-
ing, 1426 patients were excluded, and 1380 patients were
found to be eligible for the study. Of these, 162 patients
had Hb <10 g/dL and were thus classified as being
anemic. All 162 patients were included in the study
(cases). A random selection of 295 patients from the
non-anemic pool was included into the study (controls).
The final sample size for the study is 457 patients.
The patients’ demographic, clinical and laboratory data
are presented in Table 1, and their medical and medica-
tion histories are presented in Table 2. The mean age of
the patients was 67.0 ± 13.6 years and 53 % were male. It
was found that 12.3 % of the patients had stage 1–2
CKD while 87.7 % of the patients had moderate to se-
vere CKD (stage 3 and above). Majority of the patients
had dyslipidemia (92.8 %), hypertension (89.3 %) and
diabetes mellitus (64.6 %). The use of angiotensin recep-
tor blockers (42.5 %), iron supplements (32.2 %) andic patients, N = 295 for non-anemic patients)
Number (%)
Anemic patients Non-anemic patients
150 (92.6) 274 (92.9)
149 (92) 259 (87.8)
146 (90.1) 55 (18.6)
112 (69.1) 183 (62)
75 (46.3) 99 (33.6)
67 (41.4) 116 (39.3)
47 (29) 51 (17.3)
43 (26.5) 19 (6.4)
35 (21.6) 54 (18.3)
19 (11.7) 36 (12.2)
5 (3.1) 15 (5.1)
3 (1.9) 13 (4.4)
3 (1.9) 12 (4.1)
69 (42.6) 78 (26.4)
59 (36.4) 135 (45.8)
38 (23.5) 107 (36.3)
33 (20.4) 44 (14.9)
30 (18.5) 31 (10.5)
8 (4.9) 20 (6.8)
5 (3.1) 22 (7.5)
13 (8) 10 (3.4)
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common.
Predictors of anemia status
A total of 21 potential predictors were identified after
performing univariate logistic regression analyses. Back-
ward elimination reduced this to 5 parameters. The po-
tential predictors identified were previous Hb, CKD
stage, hematological disorders, respiratory disorders and
use of iron supplements. Gender but not race was found
to be significant in univariate logistic regression analyses.
However, this significance was lost after multivariate lo-
gistic regression analyses.
Since gender and race were found to be significant
predictors of anemia in other studies (McClellan et al.
2004; Al-Khoury et al. 2006), the results of multivariate
logistic regression analysis using the 5 predictors found
in this study, together with gender and race, are pre-
sented in Table 3. The multivariate logistic regression
analysis using the 5 predictors alone is similar and isTable 3 Adjusted odds ratios of developing anemia
(serum Hb <10 g/dL)
Parameters Adjusted OR P-value




Female 0.90 (0.44 – 1.87) 0.786
Race
Chinese 1.00 (Reference)
Malay 1.87 (0.77 – 4.56) 0.170
Indian 1.49 (0.42 – 5.34) 0.537
Others 2.16 (0.62 – 7.54) 0.228
Clinical data
CKD stage
Stage 1 & 2 1.00 (Reference)
Stage 3 0.99 (0.23 – 4.19) 0.991
Stage 4 1.68 (0.41 – 6.86) 0.473
Stage 5 16.76 (3.49 – 80.52) <0.001*
Laboratory data
Previous Hb, g/dL 0.32 (0.23 – 0.44) <0.001*
Medical conditions
Hematological disorders 18.61 (8.44 – 41.07) <0.001*
Respiratory disorders 4.54 (1.61 – 12.83) 0.004*
Medications
Use of iron supplements
No 1.00 (Reference)
Yes 0.44 (0.21 – 0.93) 0.031*
* P < 0.05given in the Supplementary information together with
the results from the univariate logistic regression ana-
lyses (available upon request).
As expected, previous Hb was predictive of anemia de-
velopment (OR 0.32, 95 % CI 0.23-0.44, p < 0.001). In
addition, the multivariate adjusted odds of anemia devel-
opment were 16.8 times higher for a patient with stage 5
CKD (OR 16.76, 95 % CI 3.49-80.52, p < 0.001). Patients
with haematological disorders (OR 18.61, 95 % CI 8.44-
41.047, p < 0.001) and respiratory disorders (OR 4.54,
95 % CI 1.61-12.83, p = 0.004) also had higher odds of
anemia. Patients had lower odds of anemia development
if they were receiving iron supplements (OR 0.44, 95 %
CI 0.21-0.93, p = 0.031).
Discussion
This single-centre, retrospective case–control study eval-
uated the possible predictors of anemia development in
patients with CKD. Anemia (defined as Hb <10 g/dL)
was present in approximately one-third (35.4 %) of the
457 patients evaluated in the study. Although CKD-
associated anemia can be easily diagnosed and is typically
amenable to treatment (KDIGO Anemia Work Group
2012), it is known to be an adverse indicator for the pro-
gression of CKD and a critical risk multiplier for cardio-
vascular diseases. These complications associated with
anemia can lead to an increase in mortality (Silverberg
et al. 2009) and the large consumption of healthcare re-
sources (London et al. 2002). Studies have also shown that
CKD patients with Hb near normal levels experience
functional improvements and significantly better quality
of life (Moreno et al. 1996; Moreno et al. 2000). Hence,
emphasis should be placed on the prevention of anemia
development rather than treatment, since it plays a crucial
role in slowing the progression of CKD and other related
comorbidities (Rossert et al. 2005).
Previous studies have identified factors such as GFR,
gender, race, iron administration and comorbidities e.g.
diabetes mellitus as potential predictors for anemia in
CKD patients (Hsu et al. 2002; Astor et al. 2002; McClellan
et al. 2004; Gilbertson et al. 2009; Al-Khoury et al. 2006).
Some results from this study were consistent with the
previously-conducted studies where the potential for
anemia development was found to be higher in patients
with poorer renal function, lack of iron administration and
presence of comorbidities. However, some differences in
results were also observed.
Previous hemoglobin concentration
The finding that previous Hb is important for predicting
anemia is not unexpected and this supports the continual
use of Hb as a parameter for evaluating future anemic sta-
tus. However, while current KDIGO guidelines recommend
that Hb be measured at least annually in non-anemic
Lau et al. SpringerPlus  (2015) 4:233 Page 6 of 9patients with stage 3 CKD and twice a year in those with
stage 4–5 CKD (non-dialysis), the optimal frequency of
monitoring is not yet known (KDIGO Anemia Work
Group 2012). In this study, previous Hb was collected at
least two months prior to the most recent visit and up to a
year prior to this two-month period i.e. Hb values were ob-
tained between two to 14 months from the most recent
clinic visit (Fig. 2). The identification of previous Hb as an
independent predictor of anemia development in this study
suggests that a monitoring frequency of between two to
fourteen months for Hb is appropriate for predicting
anemia in this Asian CKD patient population, regardless of
their clinical history. However, this time interval is rather
wide and the effect of Hb variations within this time period
is unknown. Hence, further research on the use of previous
Hb values from different time periods to determine how
dated Hb levels can be before they lose their predictive
value, as well as the effect of Hb variations during this time
period are needed. Knowledge of these may shed some
light on the optimal frequency of Hb measurements and
monitoring.
CKD stage
The risk of anemia development was found to increase
significantly as CKD worsens. This finding is consistent
with previous reports from the NHANES III study which
showed that the prevalence of anemia increases as eGFR
falls (1 % at 60 ml/min/1.73 m2, 9 % at 30 ml/min/
1.73 m2 and 33 % at 15 ml/min/1.73 m2) (McFarlane
et al. 2008; Hsu et al. 2002; Coresh et al. 2003). In this
present study, stage 5 CKD patients were 16.8 times
more likely to develop anemia as compared to patients
with stage 1 and 2 CKD. Deterioration of renal function
is accompanied by a reduction in erythropoietin produc-
tion by the kidneys, which accounts for approximately
90 % of erythropoietin production in the body (Moore
and Bellomo 2011). The loss of erythropoietin results in1 year





Fig. 2 Method of data collectiondecreased red blood cell production that causes anemia.
This explains why worsening renal function increases
the risk of anemia development.
Comorbidities
While diabetes was found to be an independent predictor
of Hb levels in a study involving 468 CKD patients (Al-
Khoury et al. 2006), it was not found to increase the odds
of anemia development in this study. Instead a history of
hematological and respiratory disorders conferred greater
odds of anemia in our patient population.
A total of 201 patients (44.0 %) had hematological dis-
orders, which included alpha-thalassemia and previous
history of anemia or episodes of anemia (within the one-
year period of data collection) with etiologies other than
CKD. Patients with a history of such disorders are
expected to have greater odds for developing anemia
subsequently, as they are already at risk. This suggests
that any CKD patient who presents with a hematological
disorder should be more closely monitored for anemia.
Similarly, patients with respiratory disorders such as
chronic obstructive pulmonary disease (COPD) and
asthma had higher odds of developing anemia. A recent
study found a high prevalence of CKD in patients with
COPD, and chronic inflammation associated with COPD
is considered to contribute to anemia development
(Incalzi et al. 2010). Optimal management of comorbid
respiratory conditions may therefore reduce the odds of
developing anemia.
Use of iron supplements
This study showed that patients without iron supplemen-
tation had approximately twice the odds of acquiring
anemia compared to patients who do. This was similarly
found in a study conducted in hemodialysis patients where
intravenous iron administration was associated with higher
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poor dietary intake or bleeding, eventually leading to a re-
duction in formation of red blood cell Hb, causing hypo-
chromic microcytic anemia (Fishbane and Singh 2009).
Thus, iron supplementation is necessary for optimal man-
agement of anemia and can in fact attenuate the progres-
sion of anemia in CKD (Kim et al. 2011).
Gender and race
Gender and race have been found to have significant as-
sociations with anemia in CKD patients in other studies
(McClellan et al. 2004; Al-Khoury et al. 2006). McClellan
et al. (McClellan et al. 2004) reported higher odds of de-
veloping anemia in female patients. Differences in the
prevalence of anemia by racial groups such as in Cauca-
sian, African-American, Native American, Hispanic and
Asian patients were also evident. However, such gender
and race differences were not identified in this study. Fe-
male patients in the study by McClellan et al. had lower
Hb concentrations than male patients, which likely ex-
plain why females had greater risk of developing anemia
(McClellan et al. 2004). Although the univariate analysis
showed female patients having higher odds of developing
anemia in this study, this statistical significance was lost
after adjustment. As our multivariate analysis already
accounted for the patients’ Hb concentrations by taking
their previous Hb into consideration, this could explain
the lack of association between gender and anemia in
this study. The Singapore population is made up of 3
major racial groups, namely Chinese, Malay and Indians.
This is vastly different from the ethnic composition of
the US population. This study did not show patients
from either racial group having higher odds of develop-
ing anemia. However, this should be further confirmed
by future studies with larger sample size.
Limitations
This study is not without limitations. Firstly, this was a
single-center study and the number of anemic patients
(162) in our study was small. As such we could not per-
form external validation of the model that we had con-
structed. This could have potentially introduced biases
into the final analysis and limited the generalizability of
the findings to the entire anemic CKD population in
Singapore.
Next, the cross-sectional nature of the study limits the
ability to show any direct cause and effect relationship
between the parameters collection and anemia develop-
ment. As only two sets of Hb level readings were col-
lected, it was not possible to determine any trend or
monitor for fluctuations in Hb level readings across the
one-year data collection period of each patient. Missing
data from the electronic medical records also posed
challenges in collecting complete information for eachpatient. Additionally, the inclusion of patients with
hematological disorders and previous history of anemia,
albeit not secondary to CKD, could have confounded the
results. Other novel markers of anemia such as hepcidin
were also not obtained as they were not routinely
measured in our clinical setting.
Despite the limitations, this study has several advan-
tages over existing data, such as the inclusion of a
sizeable local population of non-dialysis CKD patients
naïve to ESAs. These findings may present an opportun-
ity for earlier detection and intervention in patients who
present with the predictors identified in this study before
anemia develops. Future, larger studies will need to be
conducted to determine the optimal Hb level at which
correction of these risk factors should be initiated. This
would allow for a more effective management of anemia
and potentially improved outcomes in the local CKD
population. Additionally, prediction algorithms can be
developed in the future to better predict the risk of
anemia development when patients present with these
predictors, and improve the study’s applicability in the
clinical setting.Conclusion
This study found that the probability of anemia develop-
ment was greater in our local CKD patients with lower
previous hemoglobin, more advanced CKD, presence of
haematological and respiratory disorders, as well as not
using any iron supplements.Methods
Study design
This single-centre, retrospective, case–control study
was conducted at the National University Hospital
(NUH), Singapore. Approval from the National
Healthcare Group Domain-Specific Review Board, our
local Institutional Review Board was obtained. A list of
patients with a confirmed diagnosis of CKD and were
managed by the NUH Division of Nephrology from
January 2012 to September 2012 was obtained for this
study.
All adult (≥21 years old) non-dialysis patients with
stage 1–5 CKD, who had at least two serum Hb read-
ings during the data collection period (described in
Fig. 2) were included in the study, regardless of their
Hb levels. Patients were excluded if they were receiv-
ing renal replacement therapy (RRT), their serum Hb
was not measured at their most recent clinic visit,
their medical records were unavailable or if they were
receiving erythropoiesis-stimulating agents. Informed
consent was not necessary as this was a retrospective,
case–control study.
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The method of data collection is illustrated in Fig. 2.
Data were collected and reviewed from the patients’
electronic medical records. Patients were screened to de-
termine if both their ‘Current Hb’ and ‘Previous Hb’
levels were available. ‘Current Hb’ refers to the serum
Hb at the most recent clinic visit and was used to deter-
mine whether a patient has anemia. ‘Previous Hb’ refers
to the serum Hb measured at the preceding clinic visit
and was expected to be an important predictor of anemia.
All other parameters from the patients’ preceding clinic
visit that were considered to be possible predictors of
anemia were also collected. These parameters included
demographic characteristics such as age, sex and race;
clinical data such as body mass index (BMI), CKD stage;
medical and medication histories; and laboratory data
such as serum electrolytes, urinary and hematologic pa-
rameters. The parameters were evaluated to determine if
they had any value in predicting the development of
anemia in the patients.
All data within two months prior to the most recent
clinic visit were excluded and only data that were up to
one year prior to the two-month period were included.
The two-month period for data exclusion was selected
as the body’s circulating red blood cells (RBCs) would
need to be depleted before any changes in Hb can be de-
tected. This two-month period would also be representa-
tive of the lifespan of RBCs in CKD patients (Ly et al.
2004; Nurko 2006), which is shorter than the 120 days
RBC life-span of a normal, healthy individual. The data
inclusion period was also limited to no longer than a
year as older data would have less predictive value on
anemia development. Hence, if Hb was measured mul-
tiple times in the span of the one-year period, only the
most recent results were included. By comparing
changes between the previous and current Hb levels, the
prediction models constructed can estimate the patient’s
likelihood of developing anemia at least two months
later.
Data processing
Using the collected ‘Current Hb’ levels, each patient was
classified as either being anemic or non-anemic using a
threshold level of 10 g/dL. A patient was classified as being
anemic and assigned as a “case” group if his/her current
Hb level was <10 g/dL. This is based on the KDIGO guide-
lines (KDIGO Anemia Work Group 2012) and the US
FDA’s recommendation to initiate ESAs in CKD patients
when the Hb level is <10 g/dL (FDA Drug Safety Commu-
nication 2007). Patients whose Hb was ≥10 g/dL) were
considered non-anemic and were assigned as “controls”.
The CKD stage for each patient was determined based on
their eGFR calculated using the four-variable MDRD equa-
tion for standardized creatinine.Multiple imputation was used to fill in all missing
data, as this would yield less biased results compared to
using complete case analysis (White and Carlin 2010).
This was done via sequential imputation using chained
equations. As the data to be imputed were continuous
and may have non-normal distributions, the predictive
mean matching (PMM) method was selected (Vink et al.
2014). All other covariates, including the outcome par-
ameter (i.e. current Hb), were included in the imputation
model to avoid bias. A random seed of 123 was used,
and 100 imputations were performed.Statistical analysis
The correlation between the development of anemia and
different patient parameters was determined by performing
univariate logistic regression analyses. Odds ratios (OR)
were calculated to estimate the percentage change in risk
of anemia development. Parameters with p-values <0.05
were considered statistically significant. These parameters
were subsequently used for multivariate logistic regression
analysis, and backward elimination was used to remove pa-
rameters with p-values ≥0.05 in the multivariate logistic re-
gression model. In backward elimination, parameters with
the largest p-values were removed at each stage until all
the remaining parameters had p-values <0.05. Adjusted
ORs were computed for each of the remaining parameters.
All statistical analyses were performed using Stata/SE Ver-
sion 13.1 (College Station, TX, USA).
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